Cargando…
Drug Lag and Key Regulatory Barriers in the Emerging Markets
There have been numerous investigations targeted at identifying whether a drug lag exists in the mature markets of the US, EU and Japan. This work focuses on the emerging markets because of the potential they hold for the future of the pharmaceutical industry as a consequence of rapid economic and p...
Autores principales: | Wileman, Harriet, Mishra, Arun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications Pvt Ltd
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3148610/ https://www.ncbi.nlm.nih.gov/pubmed/21829782 |
Ejemplares similares
-
Regulatory requirements for marketing fixed dose combinations
por: Jayasheel, B. G.
Publicado: (2010) -
Regulatory Considerations for Biosimilars
por: Nellore, Ranjani
Publicado: (2010) -
Key points of technical review for the registration of SARS-CoV-2 antigen/antibody tests
por: Li, Hongran, et al.
Publicado: (2021) -
Key points of technical review for the registration of SARS-CoV-2 nucleic acid tests in China
por: Li, Hongran, et al.
Publicado: (2021) -
Implications of ICH-E5: Assessment of drug's sensitivity to ethnic factors and necessity of a bridging study for global drug development
por: Gupta, Sandeep Kumar
Publicado: (2011)